1.

Record Nr.

UNISA996339091503316

Autore

Hillmen P

Titolo

Therapeutic Strategies in Lymphoid Malignancies [[electronic resource] ] : An Immunotherapeutic Approach

Pubbl/distr/stampa

Oxford, : Atlas Medical Publishing Ltd, 2005

ISBN

1-280-30974-1

9786610309740

1-84692-556-8

Descrizione fisica

1 online resource (238 p.)

Collana

Therapeutic Strategies

Altri autori (Persone)

WitzigTE

Disciplina

616.994420637

Soggetti

Cancer

Lymphatics

Lymphoma

Immunotherapy

Lymphoproliferative Disorders

Neoplasms by Histologic Type

Immunomodulation

Lymphatic Diseases

Biological Therapy

Immunoproliferative Disorders

Neoplasms

Immune System Diseases

Diseases

Therapeutics

Hemic and Lymphatic Diseases

Diagnostic Techniques and Procedures

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di contenuto

Contents; Contributors; 1. The history of immunotherapy for lymphoid malignancies; 2. Immunological markers of lymphoid malignancy; 3. Diagnostic and prognostic markers of lymphoid malignancies;  the latest genetic, cytogenetic and haematological parameters; 4. CD20: B-



cell antigen and therapeutic target; 5. Rituximab and chemotherapy for non-Hodgkin's lymphomas: improved response and survival; 6. Rituximab and chemotherapy in elderly patients with lymphomas; 7. Maintenance therapy with rituximab; 8. Interferon-alpha in lymphoid malignancies

9. Radioimmunotherapy safety: radiation protection, administration guidelines, isotope comparison, and quality of life issues10. Radioimmunotherapy with Yttrium-90-labelled ibritumomab tiuxetan (ZevalinTM) for B-cell Hodgkin's lymphoma; 11. Radioimmunotherapy combinations with other therapies for non-Hodgkin's lymphoma; 12. 131I-Tositumomab therapy for the treatment ofl ow-grade non-Hodgkin's lymphoma; 13. CD52 as a target for immunotherapy; 14. Relapsed and refractory CLL: a clinical challenge

15. Optimising the use of alemtuzumab in CLL: new therapeutic end points, disease stratification and therapy earlier in the disease course16. Alemtuzumab in combination with other therapies in B-cell lymphoproliferative disorders; 17. The role of alemtuzumab in allogeneic stem cell transplantation; 18. Alemtuzumab in T-cell malignancies; 19. Epratuzumab: A new humanised monoclonal antibody to CD22; 20. Education and management of patients undergoing immunotherapy and radioimmunotherapy; 21. Antibody therapy for chronic lymphocytic leukemia; Index

Sommario/riassunto

Targeted therapies are the focus of much research in oncology. Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the case for haematologic malignancies. The advent of immunotherapy heralds a new era particularly for patients who are refractory to more traditional therapies. Impressive results are evident using monoclonal antibodies (mAb) that a) bind with high specificity to cell-surface antigens, resulting in targeted killing of the malignant cells or b) are conjugated to radioisotopes, toxins, enzymes or drug



2.

Record Nr.

UNISANNIORML0052177

Autore

Osborne, David

Titolo

Dirigere e governare / David Osborne e Ted Gaebler ; presentazione di Sabino Cassese ; postfazione di Carlo De Filippis

Pubbl/distr/stampa

\Milano!, : Garzanti, 1995

Titolo uniforme

Reinventing government

ISBN

8811738520

Descrizione fisica

511 p. ; 21 cm

Collana

Memorie, documenti, biografie

Altri autori (Persone)

Gaebler, Ted

Disciplina

350.000973

350.007

350.0073

350.00730973

350.73

351

352.3670973

Soggetti

Stati Uniti d'America - Amministrazione pubblica - Organizzazione

Collocazione

POZZO LIB.ECON MON                5393

Lingua di pubblicazione

Italiano

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Trad. di Alessandra Dipaola, Brunella Martera.